| Nov 12 |
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
|
| Oct 31 |
One Aura Biosciences Insider Raised Stake By 232% In Previous Year
|
| Oct 21 |
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value
|
| Oct 18 |
Aura stock rallies 16% on positive bladder cancer data for bel-sar
|
| Oct 17 |
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
|
| Oct 4 |
Aura Biosciences, Inc. (NASDAQ:AURA) is a favorite amongst institutional investors who own 58%
|
| Sep 17 |
Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company
|
| Sep 12 |
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
|
| Sep 3 |
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024
|
| Aug 26 |
Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting
|
